Skip navigation
Skip navigation

Th2-mediated anti-tumour immunity: Friend or foe?

Ellyard, Julia; Simson, Ljubov; Parish, Christopher

Description

The concept that the immune system can recognise tumour cells and either eliminate them (tumour immune surveillance) or select for immunologically resistant variants (immunoediting) is gaining general acceptance by immunologists. In terms of an adaptive immune response to cancer, however, much of the research has focused on the response of cytotoxic CD8+ T lymphocytes to tumour-specific antigens and the production of Th1 cytokines by CD4+ and CD8+ T cells. In contrast, Th2-mediated immunity has...[Show more]

dc.contributor.authorEllyard, Julia
dc.contributor.authorSimson, Ljubov
dc.contributor.authorParish, Christopher
dc.date.accessioned2015-12-07T22:49:06Z
dc.identifier.issn0001-2815
dc.identifier.urihttp://hdl.handle.net/1885/26604
dc.description.abstractThe concept that the immune system can recognise tumour cells and either eliminate them (tumour immune surveillance) or select for immunologically resistant variants (immunoediting) is gaining general acceptance by immunologists. In terms of an adaptive immune response to cancer, however, much of the research has focused on the response of cytotoxic CD8+ T lymphocytes to tumour-specific antigens and the production of Th1 cytokines by CD4+ and CD8+ T cells. In contrast, Th2-mediated immunity has traditionally been viewed as favouring tumour growth, both by promoting angiogenesis and by inhibiting cell-mediated immunity and subsequent tumour cell killing. While there is evidence that components of type 2 inflammation, such as B cells and interleukin-10, do promote tumour growth, there are also many studies demonstrating the anti-tumour activity of CD4+ Th2 cells, particularly in collaboration with tumour-infiltrating granulocytes, such as eosinophils. In this review, we examine all the components of type 2 immunity and their effects on tumour growth. Collectively, from this analysis, we conclude that there is a great potential for the development of Th2-mediated immunotherapies that harness the cytotoxic activity of eosinophils.
dc.publisherBlackwell Publishing Ltd
dc.sourceTissue Antigens
dc.subjectKeywords: interleukin 10; interleukin 13; interleukin 4; adaptive immunity; angiogenesis; B lymphocyte; CD4+ T lymphocyte; CD8+ T lymphocyte; cell killing; cellular immunity; cytokine production; cytotoxic T lymphocyte; eosinophil; granulocyte; human; immunosurveil Cancer; Eosinophil; Th2 immunity; Tumour immune surveillance
dc.titleTh2-mediated anti-tumour immunity: Friend or foe?
dc.typeJournal article
local.description.notesImported from ARIES
local.identifier.citationvolume70
dc.date.issued2007
local.identifier.absfor110709 - Tumour Immunology
local.identifier.ariespublicationu6800332xPUB45
local.type.statusPublished Version
local.contributor.affiliationEllyard, Julia, College of Medicine, Biology and Environment, ANU
local.contributor.affiliationSimson, Ljubov, College of Medicine, Biology and Environment, ANU
local.contributor.affiliationParish, Christopher, College of Medicine, Biology and Environment, ANU
local.description.embargo2037-12-31
local.bibliographicCitation.startpage1
local.bibliographicCitation.lastpage11
local.identifier.doi10.1111/j.1399-0039.2007.00869.x
dc.date.updated2015-12-07T12:05:32Z
local.identifier.scopusID2-s2.0-34250020832
CollectionsANU Research Publications

Download

File Description SizeFormat Image
01_Ellyard_Th2-mediated_anti-tumour_2007.pdf261.49 kBAdobe PDF    Request a copy


Items in Open Research are protected by copyright, with all rights reserved, unless otherwise indicated.

Updated:  17 November 2022/ Responsible Officer:  University Librarian/ Page Contact:  Library Systems & Web Coordinator